8 月 4 日,东阳光药宣布,其自研乙肝小核酸新药HECN30227 已在国内递交临床试验申请,标志着东阳光药在小核酸药物研发领域迈出关键一步。截图来源:企业官微HECN30227 是东阳光药自主研发并拥有全球知识产权的 1 类新药,也是其基于小核酸技术平台开发的首款 siRNA 药物,可同时消除 cccDNA 和 intDNA 来源的 HBsAg。临床前数据表明,HECN30227 具有泛基因型...
Source Link8 月 4 日,东阳光药宣布,其自研乙肝小核酸新药HECN30227 已在国内递交临床试验申请,标志着东阳光药在小核酸药物研发领域迈出关键一步。截图来源:企业官微HECN30227 是东阳光药自主研发并拥有全球知识产权的 1 类新药,也是其基于小核酸技术平台开发的首款 siRNA 药物,可同时消除 cccDNA 和 intDNA 来源的 HBsAg。临床前数据表明,HECN30227 具有泛基因型...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.